Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can pressurized oxygen boost stem cell transplant success?

NCT ID NCT03964506

First seen Jun 09, 2026 · Last updated Jun 22, 2026 · Updated 4 times

Summary

This early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant conditioning is safe and helpful. It involves up to 24 adults with certain blood cancers or bone marrow disorders. The goal is to see if the oxygen treatment improves engraftment, reduces mouth sores, and lowers infection risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Wilmot Cancer Institute, University of Rochester

    RECRUITING

    Rochester, New York, 14642, United States

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hyperbaric oxygen therapy

What this could lead to

If it works, this could improve stem cell transplant recovery and reduce complications like infections and mouth sores.

What could go wrong

This is a very early, small pilot study (24 people) focused on safety. It may not show clear benefits, and hyperbaric oxygen has risks like ear pain or oxygen toxicity.

Conditions

The condition(s) this trial relates to.

atypical chronic myeloid leukemia, BCR-ABL1 negative chronic monocytic leukemia chronic myelomonocytic leukemia chronic neutrophilic leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Myelodysplastic Syndromes Myelodysplastic-Myeloproliferative Diseases myelodysplastic/myeloproliferative neoplasm myelofibrosis Primary Myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.